Alex Fotopoulos
Chief Tech/Sci/R&D Officer at PASSAGE BIO, INC.
Net worth: 49 065 $ as of 2024-02-28
Profile
Presently, Alex Fotopoulos occupies the position of Chief Technical Officer for Passage Bio, Inc.
In the past Mr. Fotopoulos occupied the position of Senior Vice President-Technical Operations at Ultragenyx Pharmaceutical, Inc. and Senior Vice President & Head-Technical Operations at Dimension Therapeutics, Inc. (a subsidiary of Ultragenyx Pharmaceutical, Inc.), Senior Director-Global Manufacturing Engineering at Biogen, Inc. and Vice President-Technical Operations at Momenta Pharmaceuticals, Inc.
Alex Fotopoulos received a graduate degree from Tufts University and an MBA from F.W.
Olin Graduate School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
PASSAGE BIO, INC.
0.05% | 2023-06-15 | 28,693 ( 0.05% ) | 49 065 $ | 2024-02-28 |
Alex Fotopoulos active positions
Companies | Position | Start |
---|---|---|
PASSAGE BIO, INC. | Chief Tech/Sci/R&D Officer | 2019-06-30 |
Former positions of Alex Fotopoulos
Companies | Position | End |
---|---|---|
ULTRAGENYX PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 2019-06-30 |
DIMENSION THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 2017-10-31 |
MOMENTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-04-30 |
BIOGEN INC. | Corporate Officer/Principal | 2010-12-31 |
Training of Alex Fotopoulos
Tufts University | Graduate Degree |
F.W. Olin Graduate School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
BIOGEN INC. | Health Technology |
ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
PASSAGE BIO, INC. | Health Technology |
Private companies | 2 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |